score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R611W	0.629	62.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC2 p.R611W (Missense)		Osteosarcoma-BCS514	Osteosarcoma-BCS514-Tumor-SM-2RCAR	Osteosarcoma-BCS514-Normal-SM-2RCC7
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R552*	0.6522	23.0	0.0	0.0																					0				RB1 p.R552* (Nonsense)		Osteosarcoma-BCS514	Osteosarcoma-BCS514-Tumor-SM-2RCAR	Osteosarcoma-BCS514-Normal-SM-2RCC7
Biologically Relevant				Copy Number	SMARCA4	Amplification				0.0	0.0																					0				SMARCA4 Amplification		Osteosarcoma-BCS514	BCS514_T	
Biologically Relevant				Copy Number	MLH1	Deletion				0.0	0.0																					0				MLH1 Deletion		Osteosarcoma-BCS514	BCS514_T	
Biologically Relevant				Microsatellite Stability	Supporting variants		MLH1 Deletion, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: MLH1 Deletion, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		Osteosarcoma-BCS514		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.254																									0				COSMIC Signature (version 2) 1 (25%)		Osteosarcoma-BCS514		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.604																									0				COSMIC Signature (version 2) 6 (60%)		Osteosarcoma-BCS514		
